Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03442647
Other study ID # 2017-01839
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 1, 2018
Est. completion date August 30, 2019

Study information

Verified date May 2018
Source University of Zurich
Contact Thomas F Mueller, Prof.
Phone +41 44 255 33 84
Email thomas.mueller@usz.ch
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The number of people with kidney disease is constantly rising and renal failure represents one of the major health care burdens globally. An accurate measurement of kidney function is urgently needed to better understand and treat loss of renal function. Kidneys have an intrinsic reserve capacity to respond to a higher work load by increasing filtration in their nephrons. The number of nephrons and their reserve capacity define how well kidneys can adapt to an increased demand and disease.

The degree of renal reserve capacity becomes particularly important when the number of functioning nephrons is significantly reduced either due to surgical removal of one kidney as in living kidney donation or in tumor nephrectomy or due to progressive injury as in autosomal dominant polycystic kidney disease (ADPKD). A reduced functional reserve likely reflects an impaired adaptive capacity and increased risk of accelerated loss of function in the remaining single kidney or in kidneys exposed to a disease. Despite the importance of accurately measuring baseline and reserve capacity renal function, due to the time- and laborintensive procedure, in clinical routine this testing is rarely done.

Investigators aim to measure renal functional reserve (RFR) and loss of function in patients undergoing nephrectomy (living kidney donors and renal tumor patients) as well as in patients with ADPKD.

The results should provide evidence whether renal functional reserve indeed predicts adaptive capacity and functional loss after removal of a healthy kidney (living donors), of a tumor kidney (cancer patients) or in progressive kidney disorders (ADPKD patients).

Investigators are confident that the proposed project will enhance the understanding of progressive kidney disease and with this improve donor safety, planning of tumor nephrectomy, and prediction of renal functional loss as well as provide a strong argument that dynamic renal function testing, i.e. accurate measurement of baseline and reserve capacity, is necessary in certain disease entities.


Description:

The measurement of RFR will be performed by dynamic testing of the changes in baseline glomerular filtration rate (GFR) induced by an oral protein load. Sinistrin (a polyfructosan with identical clearance characteristics to inulin) will be used to measure GFR.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date August 30, 2019
Est. primary completion date August 30, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Potential living kidney donor

- Patients with diagnosed ADPKD

- Patients with primary kidney tumor requiring nephrectomy

- Female and male patients over 18 years of age

Exclusion Criteria:

- Bilateral kidney tumor

- Kidney metastases of a tumor of other origin

- Renal failure that requires dialysis

- Pregnant patient

- Incomplete medical records

- Patients with diabetes mellitus

- Patients who cannot tolerate iv fluids

- Hypersensitivity to the active substance (sinistrin) or to any of the excipients

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
sinistrin clearance dynamic measurement
sinistrin clearance measurements will be performed before and 90 min after oral protein load

Locations

Country Name City State
Switzerland University Hospital Zurich Zürich

Sponsors (1)

Lead Sponsor Collaborator
Thomas Mueller

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary RFR predicts renal functional decline Sinistrin levels in plasma before and after oral protein load. Participants with impaired RFR are expected to have higher sinitrin levels in plasma. up to 8 months
See also
  Status Clinical Trial Phase
Completed NCT00678392 - Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Phase 3
Not yet recruiting NCT03129724 - Retrospective Study in Patients With Metastatic Renal Cancer Treated With TKI Sequence (Tyrosine Kinase Inhibitors of VEGFR) - mTOR- Axitinib Inhibitors or Anti-VEGF Antibody -Inhibiteurs mTOR - Axitinib N/A
Terminated NCT01413607 - The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Phase 4
Terminated NCT00091611 - Cultured White Cells Plus Interleukin-2 to Treat Advanced Kidney Cancer Phase 1
Terminated NCT02439008 - Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response N/A
Completed NCT01688999 - Cabozantinib for Advanced Urothelial Cancer Phase 2
Recruiting NCT05184504 - Clinical-pathological Characterization and Outcomes of Renal Cell Carcinoma in Latin American
Completed NCT04933604 - LPN in Patients With High-complex Renal Tumors
Recruiting NCT05068180 - Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients Phase 4
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Terminated NCT02543645 - A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Phase 1
Terminated NCT01712685 - Imaging Studies of Kidney Cancer Using 18F-VM4-037 Phase 2
Terminated NCT00816686 - A Phase 1 Study of the Safety and Pharmacokinetics of AGS-16M18 in Subjects With Advanced Renal Cell Cancer Phase 1
Completed NCT00537056 - Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI N/A
Completed NCT00076011 - Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma Phase 2
Completed NCT00226980 - A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma Phase 2
Terminated NCT02900248 - CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
Recruiting NCT03160274 - Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
Recruiting NCT03062410 - Quality of Life Assessment in Daily Clinical Oncology Practice for Patients With Advanced Renal Cell Carcinoma N/A
Completed NCT02924922 - Assessment of Oncological and Functional Outcomes After Robot Assisted Partial Nephrectomy Versus Laparoscopic Partial Nephrectomy N/A